Federal Register / Vol. 76, No. 8 / Wednesday, January 12, 2011 / Notices 2129 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 6, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–581 Filed 1–11–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism, Special 

Emphasis Panel, ‘‘Review of the Prenatal 

Alcohol in Sudden Infant Death Syndrome 

And Stillbirth (PASS) Network’’ (RFA HD 

10–018). 

Date: February 28, 2011. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Richard Rippe, PhD, 

Scientific Review Officer, National Institute 

on Alcohol Abuse and Alcoholism, National 

Institutes of Health, 5635 Fishers Lane, Room 

2109, Bethesda, MD 20852. 301–443–8599. 

rippera@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards., National 

Institutes of Health, HHS) 

Dated: January 5, 2011. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–580 Filed 1–11–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Neurological 

Disorders and Stroke Council. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council, 

Basic and Preclinical Programs 

Subcommittee. 

Date: February 3, 2011. 

Time: 8 a.m. to 10 a.m. 

Agenda: To discuss basic and preclinical 

programs policy. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room #7, Bethesda, MD 20892. 

Contact Person: William D. Matthew, MD, 

Director, Office of Translational Research, 

NINDS, National Institutes of Health, 6001 

Executive Blvd., Room 2137, Bethesda, MD 

20892. 301–496–1779. bill.matthew@nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.ninds.nih.gov, where and agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 5, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–579 Filed 1–11–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders And Stroke; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Neurological 

Disorders and Stroke Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council 

Clinical Trials Subcommittee. 

Date: February 2–3, 2011. 

Closed: February 2, 2011, 6:30 p.m. to 7:45 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Open: February 3, 2011, 8 a.m. to 10 a.m. 

Agenda: To discuss clinical trials policy. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room #10, Bethesda, MD 20892. 

Contact Person: Petra Kaufmann, MD., 

Director, Office of Clinical Research-NINDS, 

National Institutes of Health, Neuroscience 

Center-Room 2216, 6001 Executive Blvd., 

Bethesda, MD 20892. 301–496–9135. 

Kaufmanp2@ninds.nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

mstockstill on DSKH9S0YB1PROD with NOTICES

2130 Federal Register / Vol. 76, No. 8 / Wednesday, January 12, 2011 / Notices 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.ninds.nih.gov, where and agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 5, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–577 Filed 1–11–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Inhibitors of the Plasmodial 

Surface Anion Channel as 

Antimalarials 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Provisional Patent 

Application No. 61/083,000, filed July 

23, 2008 [HHS Ref. No. E–202–2008/0– 

US–01], now expired and PCT Patent 

Application No. PCT/US09/50637 [HHS 

Ref. No. E–202–2008/0–PCT–02] filed 

July 15, 2009, which published as WO/ 

2010/011537 on January 28, 2010, both 

applications entitled ‘‘Inhibitors of the 

Plasmodial Surface Anion Channel As 

Antimalarials,’’ and all continuing 

applications and foreign counterparts to 

Microbiotix, Inc., having a place of 

business in Worcester, Massachusetts. 

The patent rights in these inventions 

have been assigned to the United States 

of America. 

The prospective exclusive license 

territory may be ‘‘worldwide’’, and the 

field of use may be limited to 

‘‘prevention and treatment of malaria in 

humans.’’ 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

February 11, 2011 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Kevin W. Chang, PhD, 

Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–5018; Facsimile: (301) 402– 

0220; E-mail: changke@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

subject technologies are antimalarial 

small molecule inhibitors of the 

plasmodial surface anion channel 

(PSAC), an essential nutrient acquisition 

ion channel expressed on human 

erythrocytes infected with malaria 

parasites. These inhibitors were 

discovered by high-throughput 

screening of chemical libraries and 

analysis of their ability to kill malaria 

parasites in culture. Two separate 

classes of inhibitors were found to work 

synergistically in combination against 

PSAC and killed malaria cultures at 

markedly lower concentrations than 

separately. These inhibitors have high 

affinity and specificity for PSAC and 

have acceptable cytotoxicity profiles. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within thirty (30) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: January 6, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–549 Filed 1–11–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of the Secretary 

Exercise of Authority Under Section 

212(d)(3)(B)(i) of the Immigration and 

Nationality Act 

AGENCY: Office of the Secretary, DHS. 

ACTION: Notice of determination. 

Authority: 8 U.S.C. 1182(d)(3)(B)(i). 

Following consultations with the 

Secretary of State and the Attorney 

General, I hereby conclude, as a matter 

of discretion in accordance with the 

authority granted to me by section 

212(d)(3)(B)(i) of the Immigration and 

Nationality Act (INA), 8 U.S.C. 

1182(d)(3)(B)(i), as amended, as well as 

the foreign policy and national security 

interests deemed relevant in these 

consultations, that subsection 

212(a)(3)(B)(iv)(VI) of the INA, 8 U.S.C. 

1182(a)(3)(B)(iv)(VI), shall not apply, 

with respect to an alien, for the 

provision of material support to the All 

India Sikh Students Federation-Bittu 

Faction, provided that the alien satisfies 

the relevant agency authority that the 

alien: 

(a) Is seeking a benefit or protection 

under the INA and has been determined 

to be otherwise eligible for the benefit 

or protection; 

(b) Has undergone and passed all 

relevant background and security 

checks; 

(c) Has fully disclosed, to the best of 

his or her knowledge, in all relevant 

applications and interviews with U.S. 

government representatives and agents, 

the nature and circumstances of each 

provision of material support and any 

other activity or association falling 

within the scope of section 212(a)(3)(B) 

of the INA, 8 U.S.C. 1182(a)(3)(B); 

(d) Has not participated in, or 

knowingly provided material support to, 

terrorist activities that targeted 

noncombatant persons or U.S. interests; 

(e) Poses no danger to the safety and 

security of the United States; and 

(f) Warrants an exemption from the 

relevant inadmissibility provision in the 

totality of the circumstances. 

Implementation of this determination 

will be made by U.S. Citizenship and 

Immigration Services (USCIS), in 

consultation with U.S. Immigration and 

Customs Enforcement (ICE), or by U.S. 

consular officers, as applicable, who 

shall ascertain, to their satisfaction, and 

in their discretion, that the particular 

applicant meets each of the criteria set 

forth above. 

This exercise of authority may be 

revoked as a matter of discretion and 

mstockstill on DSKH9S0YB1PROD with NOTICES